Drugs / TNTL
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06817265 Comparator | Apr 2025 → Aug 2026 overdue | diabetic retinopathy | Beletalent (Zhuhai) Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06817265 ↗ |
| Route | Oral | “oral, 4 tablets, 3 times a day, after meals.” NCT06817265 ↗ |